View Author
patient hbsag hepatitis hepatitis b response level hbeag therapy peg-ifn treatment study decline genotype baseline hbeag-positive hepatology virus peginterferon serum hbv dna hbsag levels hbv genotype hbsag decline hbv dna levels probability hbeag-positive patients mutant antigen hbeag seroconversion liver hbeag loss seroconversion hbeag-negative peg-ifn therapy disease follow-up hepatitis b virus clearance bcp mutants hbsag loss gastroenterology result surface serum hbsag levels peginterferon alfa -2a assay hepatitis b patients prediction lamivudine hbeag-negative patients flare analysis on-treatment week 12 virological response month hepatol combination presence sonneveld erasmus mc university week 78 figure association infection interferon wt virus hbsag clearance hbv genotypes hbeag clearance virological precore cohort university 6 months post-treatment promoter janssen -10 cakaloglu y post-treatment
10 Most Recent Publications
|
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
(Article)
Zoutendijk, R. Reijnders, J.G.P. Berg, T. Hansen, B.E. Sonneveld, M.J. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Brown, A. Mutimer, D.J. Deterding, K. Hofmann, W.P. Petersen, J. Fasano, M. Buti, M. |
2013-05-01
|
|
Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues
(Article)
Zoutendijk, R. Sonneveld, M.J. Reijnders, J.G.P. Vuuren, A.J. van Biesta, P.J. Hansen, B.E. Boonstra, A. Janssen, H.L.A. |
2013-05-01
|
|
Host and Viral Predictors of Response to Antiviral Therapy in Chronic Hepatitis B
(Doctoral Thesis)
Sonneveld, M.J. |
2013-04-19
|
|
Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV
(Article)
Zoutendijk, R. Zaaijer, H.L. Janssen, H.L.A. Vries-Sluijs, T.E.M.S. de Reijnders, J.G.P. Mulder, J. Kroon, F.P. Eijk, A.C. van der Sonneveld, M.J. Man, R.A. de Ende, M.E. van der |
2012-09-15
|
|
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B
(Article)
Sonneveld, M.J. Rijckborst, V. Zeuzem, S. Heathcote, E.J. Simon, K. Senturk, H. Pas, S.D. Hansen, B.E. Janssen, H.L.A. |
2012-07-01
|
|
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: Relation to response and HBV genotype
(Article)
Sonneveld, M.J. Rijckborst, V. Janssen, H.L.A. Cakaloglu, Y. Simon, K. Heathcote, E.J. Tabak, F. Mach, T. Boucher, C.A.B. Hansen, B.E. Zeuzem, S. |
2012-01-30
|
|
Hepatitis B surface antigen monitoring and management of chronic hepatitis B
(Article)
Sonneveld, M.J. Zoutendijk, R. Janssen, H.L.A. |
2011-07-01
|
|
A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B
(Article)
Sonneveld, M.J. Rijckborst, V. Boucher, C.A.B. Zwang, L. Beersma, M.F.C. Hansen, B.E. Janssen, H.L.A. |
2011-07-01
|
|
Review article: Chronic hepatitis B - Anti-viral or immunomodulatory therapy?
(Article)
Rijckborst, V. Sonneveld, M.J. Janssen, H.L.A. |
2011-03-01
|
|
Reply
(Article)
Sonneveld, M.J. Rijckborst, V. Janssen, H.L.A. |
2011-03-01
|
